You are here: Industry Insights > thyroid cancer

News List

CStone announces positive registrational study of GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer prnasia
June 28, 2021
CStone Pharmaceuticals, a leading biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology therapies and precision medicines, today announced positive results from China registrational study of the ...
AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer drugs
May 24, 2021
AffyImmune , effective ways to use CAR T cells against solid cancers, announced today that FDA granted Fast Track designation to its lead compound, for the treatment of anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer.
Roche gets FDA approval of Gavreto in advanced or metastatic RET-mutant and RET fusion-positive thyroid cancers pharmaceutical-business-review
December 07, 2020
Roche announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto (pralsetinib) for the treatment of adult and paediatric patients 12 years of age and older with advanced or metastatic rearranged during transfection (RET)-mutant ...
Genentech gets US FDA nod for Gavreto to treat RET-mutant, RET fusion-positive thyroid cancers expresspharma
December 03, 2020
Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations.
BDR Pharma launches generic version of Lenvatinib in India expresspharma
October 22, 2020
It is indicated for the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer.
Lilly Receives FDA Approval for Treatment of RET-Driven Lung and Thyroid Cancers americanpharmaceuticalreview
May 14, 2020
Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) approved Retevmo™ (selpercatinib, 40 mg & 80 mg capsules).
Lilly secures FDA approval for Retevmo to treat lung/thyroid cancers pharmaceutical-technology
May 12, 2020
Eli Lilly has secured accelerated approval from the US Food and Drug Administration (FDA) for the use of Retevmo (selpercatinib) to treat lung and thyroid cancers.
US FDA approves Retevmo for lung, thyroid cancers with certain genetic mutations expresspharma
May 11, 2020
It is the first therapy approved specifically for cancer patients with the RET gene alterations.
Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer americanpharmaceuticalreview
January 02, 2020
Eli Lilly and Company announced the opening of the LIBRETTO-531 clinical trial for selpercatinib, also known as LOXO-292, for treatment-naïve RET-mutant medullary thyroid cancer (MTC) patients.
AstraZeneca’s selumetinib flops in thyroid cancer, adding to list of failures fiercepharma
July 30, 2018
As it has been tussling over licensing checks and trying to gain a reprieve, AstraZeneca quietly announced in the midst of its quarterly update this morning that selumetinib has once again missed the mark in a cancer test.

Previous page 1 2 Next page